Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.2%

1 terminated/withdrawn out of 24 trials

Success Rate

95.7%

+9.2% vs industry average

Late-Stage Pipeline

29%

7 trials in Phase 3/4

Results Transparency

9%

2 of 22 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
7(29.2%)
N/A
7(29.2%)
Phase 4
4(16.7%)
Phase 3
3(12.5%)
Phase 1
3(12.5%)
24Total
Phase 2(7)
N/A(7)
Phase 4(4)
Phase 3(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials
NCT00200174Not ApplicableCompleted

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

Role: collaborator

NCT00062179Phase 2Completed

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Role: collaborator

NCT00038012Not ApplicableCompleted

rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin

Role: collaborator

NCT00137852Phase 2Completed

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Role: collaborator

NCT00582660Phase 2Completed

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

Role: collaborator

NCT00544232Phase 3Completed

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Role: collaborator

NCT00146588Not ApplicableCompleted

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

Role: collaborator

NCT00612638Phase 1Completed

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

Role: collaborator

NCT00581971Phase 1Completed

Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer

Role: collaborator

NCT00072319Phase 2Completed

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Role: collaborator

NCT00353015Phase 2Completed

Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract

Role: collaborator

NCT00231829Phase 2Terminated

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

Role: collaborator

NCT00861276Phase 4Completed

Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit

Role: collaborator

NCT00777075Phase 4Completed

L-Arginine and Erectile Dysfunction

Role: collaborator

NCT00628225Phase 4Completed

Smoking Cessation in Patients With COPD (SMOCC) in General Practice

Role: collaborator

NCT00470002Phase 1Completed

Effects of Growth Hormone on the Nitric Oxide Pathway

Role: collaborator

NCT00211952Phase 3Suspended

Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients

Role: collaborator

NCT00001995Not ApplicableCompleted

A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

Role: lead

NCT00002267Not ApplicableCompleted

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Role: lead

NCT00002343Phase 4Completed

A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS

Role: lead